

Future cancer patients will be treated individually

Redeye Fight Cancer 2021 21. January 2021, Stockholm

Ole Thastrup CEO 2cureX

Agenda Topics

- 2cureX is defined by a strong foundation
- The IndiTreat[®] test addressing an unmet medical need
- Status on clinical trial in colorectal cancer (CRC)
- Patient and health economic consequences of using IndiTreat[®]
- Strong commercial roadmap 2021-2023
- Strengthening the executive team
- An attractive investment-case



Ole Thastrup CEO & Founder


Contact:

Ole Thastrup, CEO ot@2curex.com www.2curex.com






2cureX is defined by a strong foundation





IndiTreat[®] product pipeline addresses high profile cancer areas





IndiTreat-guided treatment in third-line therapy

Metastatic colorectal cancer (mCRC)



One patient tested towards a panel of off-label drugs



One treatment identified as effective




Source: Data on file 2curex '21

Because patients are individuals

IndiTreat-guided treatment in first-line therapy

Metastatic colorectal cancer (mCRC)



Several patients tested towards one standard treatment




55% of patients show resistance toward specific standard treatment



Source: Data on file 2curex '21


Because patients are individuals

Clinical trial on track - Last patient treated





Patient data presenting 3. line and 1. line treatment




Positive outcome of clinical study will have the following impact on treatment of mCRC:

- Immediate implementation in **third-line treatment** using standard and off-label treatments
- Immediate implementation in **first-line treatment** using guideline based standard treatments



IndiTreat[®] delivers patient and health economic benefits


IndiTreat® increases response rate and decreases time to response for colon cancer patients




Patient Benefit

- Increased treatment efficacy
- Avoiding drug resistance

Using IndiTreat® increases the average quality of life



The ICER¹ shows that IndiTreat[®] is value for money, especially when used in first line



Health Economic Benefit

- Increased quality of life
- Improved Incremental costeffectiveness ratio (ICER)



Source: Incentive A/S Health Economics

- because cancer patients are individuals

	2021	2022	2023
Product Focus	Colorectal	Colorectal, Ovarian, Pancreatic	Colorectal, Ovarian, Pancreatic, Breast
Market Focus	Nordics	EU markets + UK	EU markets + UK + Selected Asian markets
Target Customers	Key cancer centers	Larger Regional Hospitals	General Hospitals
Sales Organization	Own sales reps (n=5) IVD distributors	Own sales organization (n=10) IVD distributors	Own sales organization (n=20) Global IVD partner ?
Sales Process	Evaluation deals Early-stage pricing	Commercial Deals	Commercial Deals
Product development	Pancreatic Cancer, Ovarian Cancer, Breast Cancer and Automation	Breast Cancer, Immuno Oncology, Automation	New Cancer Entities



A Clinical and Commercial partner base is in place






COVID impacts cancer market dynamics

Clin Colorectal Cancer; 2020 Dec 05. Article in English | MEDLINE | ID: mdl-33384244

Primary study | **T** See in Epistemonikos







Strengthening the Executive team

On 1. February 2021 Fernando Andreu will become the new CEO of 2cureX.

Ole Thastrup will transition into the role of CSO with responsibility for 2cureX's clinical and scientific activities.

Fernando is an international Biotech executive with extensive experience from bringing commercial value into early IVD companies and large international diagnostic companies.



Fernando Andreu CEO (from 1. Febr 2021)

Redeye Interview with Fernando Andreu and Ole Thastrup on 2th of February 2021



An attractive investment-case

- 2cureX is meeting an urgent medical need in cancer treatment
- 2cureX has introduced the world's first CE-marked and ISO13485 compliant Microtumor test (IndiTreat[®])
- Positive results from clinical trial in colorectal cancer influence guide-line based treatment
- 2cureX has a strong clinical pipeline in four major cancers
- IndiTreat[®] is patent protected in major markets
- 2cureX is strengthening its management and commercial activities

Thank you for your attention !





